首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症癌症診斷

下一代癌症診斷市場規模、佔有率和成長分析（按產品/服務、技術、癌症類型、應用、最終用途和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1900127

下一代癌症診斷市場規模、佔有率和成長分析（按產品/服務、技術、癌症類型、應用、最終用途和地區分類）—2026-2033年產業預測

Next Generation Cancer Diagnostics Market Size, Share, and Growth Analysis, By Product and Services (Products, Services), By Technology, By Cancer Type, By Application, By End Use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計下一代癌症診斷市場規模在 2024 年將達到 188.4 億美元，從 2025 年的 223.3 億美元成長到 2033 年的 868.1 億美元，在預測期（2026-2033 年）內複合年成長率為 18.5%。

在創新診斷設備、試劑盒和試劑商業化的推動下，下一代癌症診斷市場正經歷著快速就地檢驗(POCT) 的變革性轉變。預計這一轉變將推動市場成長，尤其是在伴隨診斷興起的情況下，伴隨診斷對於提供先進的個人化基因組醫學至關重要。全球各種癌症發生率的不斷上升凸顯了對先進診斷工具的需求，這些工具能夠促進早期發現，從而改善治療效果。隨著新型生物標記的不斷湧現，癌症診斷的準確性和成本效益也不斷提高。對微創技術的關注進一步強調了早期發現對於實現積極患者預後的關鍵作用，有助於應對與癌症死亡率上升相關的重大醫療保健挑戰。

下一代癌症診斷市場促進因素

對個人化醫療日益成長的需求正顯著推動下一代癌症診斷市場的擴張。這種方法著重為每位患者量身定做治療方案，充分考慮其獨特的基因組成和其他特徵。該領域的先進診斷工具在識別最有可能對標靶治療良好反應的患者方面發揮關鍵作用。隨著越來越多的醫療專業人員認知到這些客製化治療策略的益處，他們對創新診斷解決方案的依賴性日益增強，從而推動了市場成長，並最終改善了癌症患者的治療效果。

下一代癌症診斷市場面臨的限制因素

由於報銷政策不明朗，下一代癌症診斷市場面臨許多挑戰，阻礙了創新技術的廣泛應用。這種不確定性對醫療服務提供者和患者都帶來了障礙，因為這使得證明先進診斷檢測相關成本的合理性變得更加困難。各國、各地區和各醫療體系的報銷政策差異進一步加劇了這個問題。許多此類政策仍不完善，難以就尖端診斷技術的合理報銷方式達成共識。因此，經濟因素可能會阻礙醫療服務提供者在臨床實踐中全面應用這些寶貴的工具，從而限制其對患者照護的潛在影響。

下一代癌症診斷市場趨勢

下一代癌症診斷市場正經歷著向液態生物檢體檢測的重大轉變，液體活體組織切片檢測因其革新癌症診斷和後續觀察的潛力而日益受到認可。透過對血液和尿液等體液進行非侵入性分析，這些檢測方法相比傳統的組織切片檢查，提供了更安全、更經濟的選擇。液體活體組織切片檢測能夠及時、準確地提供癌症的存在和進展資訊，這推動了其在醫療服務提供者和患者中的快速普及。這也促使許多公司投入大量資金，致力於創新和提升液態生物檢體技術的有效性，從而進一步推動了市場成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Roche Holding AG（Switzerland）
Thermo Fisher Scientific Inc.（USA）
Illumina, Inc.（USA）
Abbott Laboratories（USA）
QIAGEN NV（Germany/Netherlands）
Agilent Technologies, Inc.（USA）
Bio-Rad Laboratories, Inc.（USA）
Becton, Dickinson and Company（BD）（USA）
Myriad Genetics, Inc.（USA）
Guardant Health, Inc.（USA）
Exact Sciences Corporation（USA）
Danaher Corporation（USA）
Siemens Healthineers AG（Germany）
Hologic, Inc.（USA）
GE Healthcare（USA）
Novartis AG（Switzerland）
Merck KGaA（Germany）
Sysmex Corporation（Japan）
Invitae Corporation（USA）

結論與建議

簡介目錄

Product Code: SQMIG35A2226

Next Generation Cancer Diagnostics Market size was valued at USD 18.84 Billion in 2024 and is poised to grow from USD 22.33 Billion in 2025 to USD 86.81 Billion by 2033, growing at a CAGR of 18.5% during the forecast period (2026-2033).

The market for next-generation cancer diagnostics is experiencing a transformative shift towards rapid point-of-care testing, driven by the commercialization of innovative diagnostic devices, kits, and reagents. This transition is anticipated to elevate market growth, particularly with the rise of companion diagnostics, which are becoming essential in delivering advanced, personalized genomic medicine. The increasing global incidence of various cancers underscores the urgency for sophisticated diagnostic tools that facilitate early detection and subsequently improve treatment outcomes. As new biomarkers are continually developed, the accuracy and cost-effectiveness of cancer diagnostics enhance. The focus on minimally invasive techniques further emphasizes the critical role of early detection in achieving favorable patient outcomes, addressing significant healthcare challenges associated with rising cancer mortality rates.

Top-down and bottom-up approaches were used to estimate and validate the size of the Next Generation Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Next Generation Cancer Diagnostics Market Segments Analysis

Global Next Generation Cancer Diagnostics Market is segmented by Product and Services, Technology, Cancer Type, Application, End Use and region. Based on Product and Services, the market is segmented into Products and Services. Based on Technology, the market is segmented into Next-generation sequencing (NGS), Polymerase chain reaction (PCR), DNA microarrays, Multiplexing and Other technologies. Based on Cancer Type, the market is segmented into Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Cervical cancer, Liver cancer and Other cancer types. Based on Application, the market is segmented into Screening and early detection, Prognostics and monitoring, Therapy selection, Recurrence monitoring and Other applications. Based on End Use, the market is segmented into Hospitals & clinics, Diagnostic laboratories, Academic & research institutions and Other end users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Next Generation Cancer Diagnostics Market

The increasing demand for personalized medicine significantly contributes to the expansion of the next generation cancer diagnostics market. This approach focuses on customizing treatments to suit individual patients, taking into account their unique genetic makeup and other specific features. Advanced diagnostic tools in this sector play a crucial role by identifying patients who are most likely to respond favorably to targeted therapies. As more healthcare professionals recognize the advantages of these tailor-made treatment strategies, the reliance on innovative diagnostic solutions intensifies, thereby propelling market growth and enhancing patient outcomes in cancer care.

Restraints in the Next Generation Cancer Diagnostics Market

The Next Generation Cancer Diagnostics market faces significant challenges due to unclear reimbursement policies, which hinder the adoption of innovative technologies. This uncertainty creates obstacles for healthcare providers and patients, as justifying the costs associated with advanced diagnostic tests becomes complicated. Variability in reimbursement policies across different countries, regions, and healthcare systems further exacerbates the issue. Many of these policies remain underdeveloped, leading to a lack of consensus on appropriate reimbursement methods for these cutting-edge diagnostics. Consequently, the financial implications can deter healthcare providers from fully integrating these valuable tools into clinical practice, limiting their potential impact on patient care.

Market Trends of the Next Generation Cancer Diagnostics Market

The Next Generation Cancer Diagnostics market is witnessing a significant shift towards liquid biopsy tests, which are increasingly recognized for their potential to revolutionize cancer diagnosis and monitoring. By utilizing non-invasive methods to analyze bodily fluids such as blood and urine, these tests offer a safer, more cost-effective alternative to traditional tissue biopsies. Their ability to provide timely and precise insights into cancer presence and progression is driving their rapid adoption among healthcare providers and patients alike. Consequently, this trend has attracted substantial investments from companies aiming to innovate and enhance the efficacy of liquid biopsy technologies, further propelling market growth.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Next Generation Cancer Diagnostics Market Size by Product and Services & CAGR (2026-2033)

Market Overview
Products
- Instruments
- Kits & consumables
Services

Global Next Generation Cancer Diagnostics Market Size by Technology & CAGR (2026-2033)

Market Overview
Next-generation sequencing (NGS)
Polymerase chain reaction (PCR)
DNA microarrays
Multiplexing
Other technologies

Global Next Generation Cancer Diagnostics Market Size by Cancer Type & CAGR (2026-2033)

Market Overview
Breast cancer
Lung cancer
Colorectal cancer
Prostate cancer
Cervical cancer
Liver cancer
Other cancer types

Global Next Generation Cancer Diagnostics Market Size by Application & CAGR (2026-2033)

Market Overview
Screening and early detection
Prognostics and monitoring
Therapy selection
Recurrence monitoring
Other applications

Global Next Generation Cancer Diagnostics Market Size by End Use & CAGR (2026-2033)

Market Overview
Hospitals & clinics
Diagnostic laboratories
Academic & research institutions
Other end users

Global Next Generation Cancer Diagnostics Market Size & CAGR (2026-2033)

North America (Product and Services, Technology, Cancer Type, Application, End Use)
- US
- Canada
Europe (Product and Services, Technology, Cancer Type, Application, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product and Services, Technology, Cancer Type, Application, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product and Services, Technology, Cancer Type, Application, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Product and Services, Technology, Cancer Type, Application, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Germany/Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (BD) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Invitae Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments